SCHEMBL2523113

SCHEMBL2523113

COc1cc(/C=C(\C(=O)O)c2ccccc2)ccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
ALDH1A1 P00352 2/20 0.62
AKR1C3 P42330 2/20 0.61
POLB P06746 1/20 0.60
MAPT P10636 2/20 0.58
KDM4E B2RXH2 3/20 0.57
GAA P10253 1/20 0.57
KDM1A O60341 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA3 P07451 1/20 0.55
PKM P14618 1/20 0.55
CSNK2A2 P19784 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA5A P35218 1/20 0.55
SNCA P37840 1/20 0.55
CA7 P43166 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951324 1.00 MEN1 (0.62) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL2951322 1.00 MEN1 (0.62) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL2037298 0.91 MAPT (0.58) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL14125351 0.89 CXCL12 (0.62) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL14125352 0.89 CXCL12 (0.62) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL27640499 0.89 MEN1 (0.62) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL27176082 0.86 AKR1C2 (0.65) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL2524591 0.86 HTT (0.58) MEN1KMT2AALDH1A1AKR1C3POLB
SCHEMBL28899315 0.84 AKR1C3 (0.75) AKR1C3AKR1C1AKR1C2PTGS2
SCHEMBL28461838 0.84 AKR1C3 (0.75) AKR1C3AKR1C1AKR1C2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801087-B1 CIS-1,2-SUBSTITUTED STILBENE DERIVATIVES FOR TREATING AND/OR PREVENTING DIABETES INST RADIATION MED AMMS PLA (CN) 2012-08-29 EP disclosed
US-8039513-B2 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2011-10-18 US disclosed
US-20090161561-A1 Method and system for determining characters of channels HUAWEI TECHNOLOGIES CO., LTD 2009-06-25 US disclosed
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2009-03-19 US disclosed
EP-1801087-A1 CIS-1,2-SUBSTITUTED STILBENE DERIVATES AND THE USE THEREROF FOR MANUFACTURING MEDICAMENTS FOR TREATING MEDICAMENTS FOR TREATING AND/OR PREVENTING DIABETES Institute of Radiation Medicine, Academy of Military Medical Sciences Pla (CN) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes SLC5A1, SLC5A2, SLC2A1 MEN1 1238/4885KMT2A 4751/4885ALDH1A1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.